反応式
CS(O[CH2:6][CH2:7][C:8]1[C:9]([C:29]([F:32])([F:31])[F:30])=[N:10][N:11]([CH2:13][C:14]([NH:16][C:17]2[S:21][C:20]3[CH2:22][CH2:23][CH2:24][CH2:25][C:19]=3[C:18]=2[C:26](=[O:28])[NH2:27])=[O:15])[CH:12]=1)(=O)=O.[CH3:33][NH2:34].C(O)=O>CN(C=O)C>[CH3:33][NH:34][CH2:6][CH2:7][C:8]1[C:9]([C:29]([F:30])([F:32])[F:31])=[N:10][N:11]([CH2:13][C:14]([NH:16][C:17]2[S:21][C:20]3[CH2:22][CH2:23][CH2:24][CH2:25][C:19]=3[C:18]=2[C:26]([NH2:27])=[O:28])=[O:15])[CH:12]=1参加物
5
反応物 3
生成物 1
試薬・触媒・溶媒 1
反応条件
- 温度
- 120 °C
実験手順
The 2-(1-(2-(3-carbamoyl-4,5,6,7-tetrahydrobenzo[b]thiophen-2-ylamino)-2-oxoethyl)-3-(trifluoromethyl)1H-pyrazol-4-yl)ethyl methanesulfonate (30 mg, 0.061 mmol) was dissolved in DMF (1 mL) and methylamine (2 M in THF, 1 mL, 2 mmol) added. The reaction mixture was heated at 120° C. for 5 min in the microwave. The THF was removed in vacuo and the reaction mixture filtered and purified by preparative reverse phase HPLC to give the formic acid salt of the desired product (3.6 mg, 0.008 mmol, 12%).
後処理
- customThe THF was removed in vacuo
- filtrationthe reaction mixture filtered
- custompurified by preparative reverse phase HPLC
出典と根拠
- ORDレコード
- ord-4fcfae59353649e49cdea4ee85fd3982
- 出典データセット
- uspto-grants-2010_10
- 特許番号
- US07820707B2
関連ノート
読み込み中…